quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:04:07·38d
SECFiling
Monte Rosa Therapeutics Inc. logo

Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

GLUE· Monte Rosa Therapeutics Inc.
Health Care
Original source

Companies

  • GLUE
    Monte Rosa Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 19UpdateWells Fargo$11.00
  • Feb 15UpdateWedbush$11.00
  • Jan 3UpdateWells Fargo$18.00
  • Oct 13UpdateUBS$22.00
  • Aug 15UpdateJefferies$20.00
  • Apr 28UpdateCredit Suisse$19.00

Related

  • PR4d
    Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
  • SEC7d
    SEC Form 144 filed by Monte Rosa Therapeutics Inc.
  • INSIDER8d
    SEC Form 4 filed by Warmuth Markus
  • INSIDER13d
    SEC Form 4 filed by Nickson Philip
  • INSIDER16d
    SEC Form 4 filed by Bowen Matthew
  • INSIDER16d
    SEC Form 3 filed by new insider Bowen Matthew
  • SEC35d
    Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.
  • SEC36d
    SEC Form S-8 filed by Monte Rosa Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022